These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
250 related items for PubMed ID: 16570152
1. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Matsue K, Takeuchi M, Koseki M, Uryu H. Ann Hematol; 2006 Aug; 85(8):542-4. PubMed ID: 16570152 [No Abstract] [Full Text] [Related]
2. Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer. Matsue K, Matsuo K, Fujiwara H, Iwama K, Hayama BY, Kimura S, Yamakura M, Takeuch M. Thromb Haemost; 2009 Jun; 101(6):1170-1. PubMed ID: 19492163 [No Abstract] [Full Text] [Related]
3. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure. Sonmez M, Cobanoglu U, Ovali E, Omay SB. J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422 [No Abstract] [Full Text] [Related]
5. Bone marrow necrosis secondary to imatinib usage, mimicking spinal metastasis on magnetic resonance imaging and FDG-PET/CT. Aras Y, Akcakaya MO, Unal SN, Bilgic B, Unal OF. J Neurosurg Spine; 2012 Jan; 16(1):57-60. PubMed ID: 22017257 [Abstract] [Full Text] [Related]
6. Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia. Matsue K, Aoki T, Odawara J, Kimura S, Yamakura M, Takeuchi M. Leuk Res; 2009 Jun; 33(6):867-9. PubMed ID: 18951628 [No Abstract] [Full Text] [Related]
7. Bone marrow necrosis related to imatinib mesylate therapy for cml bilineal blast crisis. Campiotti L, Codari R, Appio L, Ultori C, Solbiati F, Maria Grandi A, Venco A. Leuk Res; 2007 Dec; 31(12):1768-70. PubMed ID: 17403537 [No Abstract] [Full Text] [Related]
8. Adverse events after imatinib mesylate therapy. Burton C, Azzi A, Kerridge I. N Engl J Med; 2002 Feb 28; 346(9):712-3. PubMed ID: 11873781 [No Abstract] [Full Text] [Related]
15. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Patel SB, Gojo I, Tidwell ML, Sausville EA, Baer MR. Leuk Lymphoma; 2011 Jul 28; 52(7):1211-4. PubMed ID: 21534873 [Abstract] [Full Text] [Related]
16. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia. Dann EJ, Fineman R, Rowe JM. J Clin Oncol; 2002 Jan 01; 20(1):354-5. PubMed ID: 11773197 [No Abstract] [Full Text] [Related]
17. Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Ishii Y, Shoji N, Kimura Y, Ohyashiki K. Intern Med; 2006 Jan 01; 45(5):339-40. PubMed ID: 16596010 [No Abstract] [Full Text] [Related]
18. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate. Cerchione C, Fabbricini R, Pane F, Luciano L. Leuk Res; 2009 Aug 01; 33(8):e104-5. PubMed ID: 19232719 [No Abstract] [Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR. Pediatr Blood Cancer; 2009 Dec 15; 53(7):1289-94. PubMed ID: 19731318 [Abstract] [Full Text] [Related] Page: [Next] [New Search]